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Abstract
Although the VGF derived peptide TLQP-21 stimulates gonadotropin-releasing hormone (GnRH) and gonadotropin
secretion, available data on VGF peptides and reproduction are limited. We used antibodies specific for the two ends of the
VGF precursor, and for two VGF derived peptides namely TLQP and PGH, to be used in immunohistochemistry and enzyme-
linked immunosorbent assay complemented with gel chromatography. In cycling female rats, VGF C-/N-terminus and PGH
peptide antibodies selectively labelled neurones containing either GnRH, or kisspeptin (VGF N-terminus only), pituitary
gonadotrophs and lactotrophs, or oocytes (PGH peptides only). Conversely, TLQP peptides were restricted to somatostatin
neurones, gonadotrophs, and ovarian granulosa, interstitial and theca cells. TLQP levels were highest, especially in plasma
and ovary, with several molecular forms shown in chromatography including one compatible with TLQP-21. Among the
cycle phases, TLQP levels were higher during metestrus-diestrus in median eminence and pituitary, while increased in the
ovary and decreased in plasma during proestrus. VGF N- and C-terminus peptides also showed modulations over the
estrous cycle, in median eminence, pituitary and plasma, while PGH peptides did not. In ovariectomised rats, plasmatic TLQP
peptide levels showed distinct reduction suggestive of a major origin from the ovary, while the estrogen-progesterone
treatment modulated VGF C-terminus and TLQP peptides in the hypothalamus-pituitary complex. In in vitro hypothalamus,
TLQP-21 stimulated release of growth hormone releasing hormone but not of somatostatin. In conclusion, various VGF
peptides may regulate the hypothalamus-pituitary complex via specific neuroendocrine mechanisms while TLQP peptides
may act at further, multiple levels via endocrine mechanisms involving the ovary.
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Introduction
The VGF gene product, and/or its derived peptides, appear to
be involved in reproduction since vgf null mice were sexually
immature and almost completely infertile [1]. The 66 kDa VGF
precursor [1–6] is composed of 617 or 615 amino acid residues (in
rat or human, respectively), and gives rise to several low molecular
weight VGF peptides which are abundant in multiple brain
regions, peripheral neurones, and certain endocrine and neuro-
endocrine cell populations [7–13]. Despite their abundance and
wide distribution, limited data are available on their role and
function/s. Among the VGF peptides with proven biological
activity are included TLQP-21 [14], TLQP-62 [15] and the
peptides called NERPs [16]. TLQP-21 was shown to act on
various mechanisms, including the regulation of energy balance
[14], inflammatory and neuropathic pain [17,18], chronic stress
[19], and gastric motility and emptying [20]. With respect to
reproduction, induction of VGF mRNA was reported in the
pituitary immediately after the estrus, in parallel with a clear-cut
decrease in certain VGF peptides, as well as changes in their
localisation in gonadotrophs and lactotrophs [21]. A distinct
seasonal modulation in cell-type-specific processing of the VGF
precursor was revealed in the anterior pituitary of female sheep
[22], while significant upregulation of VGF mRNA was found
related to reproductive maturation in baboon ovary [23]. More
recently, TLQP-21 was shown to exert a number of actions on the
rat reproductive axis [24,25]. Central administration of TLQP-21
in pubertal and adult male rats induced gonadotrophin secretion
via release of gonadotropin-releasing hormone (GnRH), and
stimulated testosterone secretion in vitro in pre-pubertal animals
[24]. In female pre-pubertal rats, TLQP-21 induced in vitro
secretion of luteinising hormone (LH) and follicle-stimulating
hormone (FSH) from the pituitary, with no detectable effect on
GnRH release from the hypothalamus [25]. On the same rats,
upon i.p. injection of the same peptide at high doses, serum LH
showed a moderate increase, while after central administration of
TLQP-21 in adults animals, the LH response was dependent on
the stage of the reproductive cycle [25]. On the whole, TLQP-21
would so far appear to affect female reproduction by stimulating
pituitary LH release. We produced antisera selective for the C-and
N-terminal portions of the VGF precursor, and for two cleaved
peptides ‘‘TLQP’’ and ‘‘PGH’’ (named from the corresponding
four N-terminal, and three C-terminal amino-acids, respectively,
immediately adjacent to their respective sites of cleavage from the
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VGF precursor), to be used for immunohistochemistry (IHC) and
enzyme-linked immunosorbent assay (ELISA), complemented
with gel chromatography. We addressed the localisation and
changes of VGF peptides in the female rat reproductive axis in
connection with the estrous cycle, as well as after ovariectomy.
Their presence and modulation in plasma was outlined in parallel,
as a clue to their possible endocrine significance. In addition, in
view of its selective distribution in the hypothalamus, the ability of
the TLQP-21 peptide to release somatostatin or growth-hormone-
releasing hormone (GHRH) was tested in vitro.
Materials and Methods
Animals and tissue samples
Sprague Dawley adult female rats (from Charles River, Italy,
200–250 g body weight) were kept at 22uC (12:12-h light/dark
cycle, lights on 7 am–7 pm), 3 to 4 rats per cage, with food and
water ad libitum. All animals were killed at the same time of day
(approximately 10 am), with a diethyl ether overdose. Group 1
(‘‘cycling rats’’) included females showing regular 4 days estrous
cycles (vaginal smears were taken daily at 8.30–9.30 during about
2 consecutive cycles, on average). Rats were killed at the age of 12–
14 weeks, at proestrus, estrus, diestrus, or metestrus (n = 12 per
each cycle phase). Group 2 rats (‘‘ovariectomy + estrogen/
progesterone treatment’’, n = 8) were bilaterally ovariectomised at
3–4 weeks’ age, hence received intraperitoneal beta-estradiol (200
ug/200 ul, 2 days before sacrifice) and progesterone (500 ug/200
ul, on the day of sacrifice). Group 3 rats (‘‘ovariectomy controls’’,
n = 7) were as for group 2, but received the corresponding solvent
only (seed oil). Rats from groups 2 and 3 were sacrificed in parallel,
4 hours after the progesterone/oil injection. All experimental
protocols were approved by the Ethical Committee at the
University of Cagliari, and were performed in accordance with
the guidelines for the care and use of animals approved by the
American Physiological Society, the EEC Council Directive of 24
November 1986 (86/609) and the relevant Italian legislation. For
ELISA experiments, the brain, hypophysis and ovaries were
extracted from each rat as follows: group 1, n = 8 per phase; group
2, n = 5; group 3, n = 4. For group 1, the median eminence was
dissected (under a stereomicroscope) from the remainder of the
hypothalamus, and the two were separately extracted. The whole
hypothalamus, inclusive of the median eminence, was taken from
rats of groups 2 and 3. Blood (approximately 5 ml) was drawn at
sacrifice (hence for cycling rats at the morning of each cycle phase
as above mentioned) from the left heart of every animal, collected
in an EDTA (1.78 mg/ml) containing tube, and rapidly centri-
fuged (3,0006g, 10–15 minutes), hence plasma was stored frozen.
Tissues were extracted in ice-cold phosphate buffered saline (PBS,
0.01 mol/l PO4, pH 7.2–7.4, 0.15 mol/l NaCl: 10 ml/g tissue)
containing protease inhibitor cocktail (P8340, Sigma-Aldrich,
Schnelldorf, Germany), homogenized for 3 minutes using an ultra
Turrax (Ika-Werke, Staufen, Germany), hence tubes were heated
in a vigorously boiling water bath for 10 minutes, and centrifuged
(3,0006g, 10 minutes). Supernatants were stored frozen until use
(220uC or lower). For IHC, rats (group 1, n = 4; groups 2 and 3,
n = 3 each) were transcardially perfused with 4% paraformalde-
hyde (in 0.2 mol/l PO4 buffer, pH = 7.2), hence brain, pituitary
and ovary were dissected out, and rinsed overnight in PBS
containing 7% sucrose. Samples were oriented in aluminum foil
moulds with cryoembedding media [26], snap-frozen and stored in
a liquid nitrogen tank (vapour phase). Sections (5–7 um) were
obtained using a cold-blade cryomicrotome [27] (Microm HM-
560, Walldof, Germany), and collected on poly-L-lysine treated
slides.
Antibodies
The antibodies used are summarized in Table 1. VGF peptides
used for immunizations (Fig. 1) encompassed: (i) the rat VGF C-
terminal nonapeptide; (ii) the N-terminal decapeptide of the rat
VGF precursor (VGF24-33, upon cleavage of the rat VGF1-23
signal peptide); (iii) the N-terminal decapeptide of rat TLQP
peptides (rat VGF556-565), and: (iv) the C-terminal nonapeptide
of PGH peptides (rat VGF422-430). These were conjugated with
bovine thyroglobulin or keyhole limpet haemocyanin, via either an
additional N-terminal D-tyrosine residue (for VGF C-terminus
and PGH), or an additional C-terminal cysteine (for VGF N-
terminus and TLQP), as previously described (Tables 1–2).
Hormone and hypothalamic factor antibodies (Table 1) showed
negligible (,0.5%) cross reactivity with other pituitary hormones
[21,22].
Characterization of VGF antibodies
Specificity was addressed in parallel via immunohistochemistry
and ELISA. In the former, labeling with each VGF antibody was
prevented by pre-absorbed with the relevant peptide (up to
50 nmol/ml). At the C-terminus of VGF, the rat sequence shows a
single amino acid difference versus human VGF (Table 2). Both
the human nonapeptide and other peptide missing the last three
C-terminal amino acids (HVLL) showed negligible reactivity in
ELISA (Table 2), while in IHC the rat VGF C-terminus antibody
showed: (i) low reactivity on human tissues; (ii) clear-cut no-
colocalisation of VGF C-terminus and HVLL immunostaining
[28]. On such basis, the latter antibody is considered to recognise a
short intact sequence at the extreme C-terminus of rat VGF.
Species differences are shown in the VGF N-terminal decapeptide
(Table 2), with very low reactivity of mouse and human forms in
ELISA. Hence, antibody reactivity would depend on a compar-
atively long portion of the immunogen sequence. Cleaved peptides
with an exposed TLQP or PGH sequence (i.e. with such sequence
present at their N-terminus, and C-terminus, respectively) can be
formed via proteolysis at the adjacent cleavage sequence: Arg553-
Pro554-Arg555, for TLQP peptides [12], and: Arg431-Arg432, for
PGH peptides. Synthetic peptides similar to immunogens, with the
addition of one extra Arginine in the location of their respective
cleavage sequence (‘‘Arginine-extended’’, see Table 2), were used
to gain insight into the potential cross-reactivity of antibodies with
native extended peptides (these may include the whole VGF
precursor, or any peptides cleaved from VGF and including the
TLQP or PGH sequence internally). In ELISA, the coating of
specific peptide antigen onto the wells, together with high antibody
dilutions, results in selection of the antibodies taking part in the
reaction, hence in a major increase in specificity for cleaved
peptides. Furthermore, most native peptides will be extended by
many more than the one (Arginine) residue we tested, thus
favouring low cross-reactivity.
Immunostaining
Sections were incubated overnight in a humid chamber, with
antibodies diluted in PBS containing 30 ml/l of normal donkey
serum, 30 ml/l of normal rat serum, and 0.02 g/l NaN3. Double
and triple immunofluorescence experiments were carried out
mixing a VGF antibody with one hormone or hypothalamic factor
antibody (Table 1) obtained in a different donor species. The
relevant species-specific secondary antibody/ies (all from donkey,
affinity purified IgG preparations absorbed with serum proteins
from multiple species, conjugated with either Cy3, Cy2 or AMCA:
Jackson Immunoresearch Laboratories, West Grove, PA) were
used to reveal the sites of primary antibody binding. Slides were
coverslipped with PBS-glycerol, observed and photographed using
VGF Peptides and Hypothalamus-Pituitary-Ovary Axis
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BX41 and BX51 fluorescence microscopes (Olympus, Milan, Italy)
equipped with Fuji S2 and S3 Pro digital cameras (Fujifilm, Milan,
Italy). Further to absorption controls (see above), routine controls
included substitution of each antibody, in turn, with PBS, the use
of pre-immune or non-immune sera, and the testing of each
secondary antibody with their respective non-relevant primary
antibodies.
Figure 1. The VGF precursor, amino acid stretches used to raise antibodies, and known/putative VGF peptides. Top panel: arrows are
aligned with 9 or 10 amino acid stretches used to raise antibodies, directed towards the site of conjugation with carrier protein. Middle panel: along
the primary sequence of VGF (not drawn to scale) are shown: dibasic cleavage sites (R, or: pR) and a cleavage-amidation site (agR), the N- and C-
terminal ends of the VGF precursor (‘‘app-‘‘ and ‘‘-hrp’’, respectively: single letter notation of the corresponding amino acids), and the signal peptide
(1–24 black box). Antibodies raised against VGF C-or N-terminus peptides are expected to react with any peptide cleaved from VGF, which includes
the corresponding sequence. Antibodies to PGH and TLQP are expected to react well with any peptide extended on the ‘‘conjugation’’ side (N-
terminal side of PGH, and C-terminal side of TLQP, respectively). Bottom panel: several known VGF peptides (relevant to the present study) together
with their MW are aligned with the precursor. ‘‘PGH-like’’ peptides are intended to outline two putative peptides, running from: the PGH sequence,
to: the N-terminal VGF24–36 peptide for the 39.8 kDa form, or to: a cleavage site (rat VGF178–179) implicated in the biosynthesis of NERP-3 for the
27.6 kDa peptide. Their hypothetical N-terminal extreme is pointed out (dotted bar).
doi:10.1371/journal.pone.0108456.g001
Table 1. Antisera and antibodies used in the study.
Antigen Specie Ref. Dilutions use
VGF peptides C-t. Rabbit Ferri et al. 1995 1:250 K/1:3 K E/I
Cocco et al. 2007
TLQP G. Pig Brancia et al. 2005 1:60 K/1:1000 E/I
D’Amato et al. 2008
PGH Rabbit D’Amato et al. 2008 1:60 K/1:1000 E/I
N-t. G. Pig Cocco et al. 2010 1:400 K/1:800 E/I
Hormones FSH Mouse Berger et al. 1990 1:500 I
GH Monkey AF Parlow 1:600 I
LH Sheep Biomol/Enzo 1:600 I
PRL Mouse Berger et al. 1990 1:600 I
GHRH Rabbit Phoenix 1:16000 E
GHRH GHRH Rabbit Phoenix 1:6000 E
h. factors GnRH Mouse Sternb 1:2000 I
SRIF Rabbit Abcam 1:20 K/
1:600
E/I
Kissp Rabbit Millipore 1:800 I
C-term: VGF C-terminus; N-term: VGF N-terminus; FSH: follicle-stimulating hormone; GH: growth hormone; LH: luteinising hormone; PRL: prolactin; h. factor:
hypothalamic factor, GHRH: growth hormone-releasing hormone; GnRH: gonadotrophin-releasing hormone; SRIF: somatostatin, Kissp: kisspeptin; Ref: references; E:
ELISA; I: immunohistochemistry.
doi:10.1371/journal.pone.0108456.t001
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ELISA
VGF assays were carried out as described previously [28–29].
Briefly, multiwell plates were coated with either the relevant VGF
peptide (Table 2), or synthetic GHRH (Bachem, Bubendorf,
Switzerland, 120 pmol/ml), as appropriate, and blocked with PBS
containing 9% normal donkey serum and 0.05% NaN3 (2 h).
Primary incubations were carried out with a mixture of the relevant
primary antibody (in PBS containing 9% normal donkey serum,
20 nmol/L aprotinin, 1 mg/ml EDTA and 0.05% NaN3), and
either samples (diluted 1:5 to 1:40), or serial dilutions of the relevant
standard peptide, or the relevant peptides to be tested for
characterization purposes (Table 2). Detection was carried out with
the relevant secondary antibody (affinity purified donkey IgG,
absorbed with serum proteins from multiple species, biotin
conjugated: 1 h, from: Jackson), streptavidin-peroxidase conjugate
(Biospa, Milan, Italy: 30 min), and tetramethylbenzidine substrate
(TMB X-tra, Kem-En-Tec Diagnostics, Taastrup, Denmark).
Optical density was measured at 450 nm using a multilabel plate
reader (Chameleon, Hidex, Turku, Finland). For the somatostatin
assay, plates were coated with donkey anti-rabbit IgG (as above,
1:3000), blocked as above, and incubated with a mixture of
somatostatin antibody (diluted in the above medium), biotin-
conjugated somatostatin (Bachem, 100 pmol/ml), and either
samples of heat-treated culture medium (diluted 1:10), or serial
dilutions of unconjugated somatostatin (Bachem). Detection was
carried out with streptavidin-peroxidase, as above. VGF assay
characterization is summarised in Table 2. GHRH and somato-
statin assays showed low intra- and inter-assay variation (CV%,
10%).
Chromatography
Extracts (2 ml) were individually loaded onto a Sephadex G-50S
column (Sigma; 2 cm261 m), equilibrated with 50 mM ammoni-
um bicarbonate and eluted with the same buffer. A molecular
weight (MW) marker kit (MWGF70: Sigma) was used for column
calibration. Fractions (3 ml) were reduced in volume with a
Vacufuge Concentrator (Eppendorf, Milan, Italy) and assessed by
ELISA. For all VGF peptides studied, overall recovery of loaded
immunoreactivity ranged between 80% and 100%.
In vitro experiments
In view of the specific localisation of TLQP peptides in median
eminence somatostatin-containing terminals, we hypothesized a
possible action onto secretion of somatostatin and its GHRH
neurone targets. Adult male rats (Sprague Dowley, 300–350 g
body weight, n = 12) were killed by decapitation, and their brain
was rapidly dissected out. Each hypothalamus (from optic chiasm
to mammilary bodies, about 2 mm wide) was incubated in
Dulbecco’s modified Eagle’s medium (DMEM, with 4.5 g/L
glucose, without glutamine) in a 95% O2 and 5% CO2
atmosphere, at 37uC, as previously described [24]. After 30 min,
the medium was removed and substituted with fresh medium
with/without TLQP-21 (1026 mol/L; n = 6 and 6 hypothalami).
After a further 45 minutes incubation, culture media were
collected, heat treated in a boiling water bath for 30 min, and
stored frozen pending somatostatin and GHRH assays.
Statistical analysis
Data were expressed as mean 6 SEM throughout. Statistical
analyses were carried out by one-way ANOVA, followed by t-test
Table 2. ELISA characterization.
Peptide Sequence IC50 CV1 CV2 % cross- reactivity
rVGF609–617
2 ––dY-IEHV LLHRP 100
C-t hVGF607–615 IEHV LLRRP 0.02 2–3 4 ,0.01
hVGF603–612 LEN YIEHV LL ,0.01
rVGF556–565
2 TLQPP ASSRR–C––
rVGF556–564 TLQPP ASSRR 100
TLQP rVGF556–567 TLQPP ASSRR R 1.1 3–5 6 122
rVGF556–576 TLQPP ASSRR
RHFHH ALPPA R
183
rVGF556–564-R
3 R-TLQPP ASSR 3.5
rVGF422–430
2 –dY-RSQEE APGH 100
PGH hVGF422–431-R
4 RSQEE APGH-R 0.3 4–6 6–8 ,0.015
hVGF419–427 RSQEE TPGH 3.5
hVGF419–428-R
4 RSQEE TPGH-R ,0.015
rVGF24–31
2 APPGR SDVYP-C–– 100
N-t rVGF23–30 APPGR PEAQP 10 3–7 5–8 ,0.001
mVGF24–31 APPGR PDVFP ,0.001
Sequence differences versus rat VGF are underlined; IC50: dose producing 50% inhibition (pmol per well); CV1 and CV2: intra and inter assay variation, respectively, C-t
and N-t: VGF C-terminus and N-terminus, respectively; 2 ‘‘immunogen’’: peptide used for conjugation to carrier protein and immunizations; used for plate coating and
assay standards; R3: Arg-extended: with addition of Arginine residue at the peptide N- or C-terminus, respectively; R4 additional Arginine residue from adjacent cleavage
site; ‘‘dY’’ and ‘‘C’’: additional d-Tyrosine, or Cysteine residue used for conjugation; r: rat, h: human, m: mouse.
doi:10.1371/journal.pone.0108456.t002
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as appropriate (StatistiXL software, www.statistixl.com), and a P,
0.05 was considered statistically significant.
Results
VGF peptide immunolocalisation
Immunoreactive VGF peptides were revealed in multiple areas
of the reproductive axis as hypothalamus, including the preoptic
area (POA) and median eminence, as well as in hypophyseal and
ovarian cells (Fig. 2 and 3). Experiments focussed on the POA
showed PGH peptide immunoreactivity in the majority of GnRH
axons and terminals (Fig. 2, A and B), with weak labeling of some
GnRH containing perikarya (not shown). The same applied to
VGF C-and N-terminus antibodies, with the latter additionally
labeling almost all kisspeptin containing fibres (Fig. 2C and D). In
the median eminence, TLQP peptides were brightly immuno-
stained (Fig. 2, E), confined to somatostatin containing axons and
terminals (Fig. 2, F). VGF C-and N-terminus peptides were far
more widely distributed throughout the external and internal
median eminence, including axons and terminals containing
GnRH (Fig. 2, G and H), or kisspeptin (VGF N-terminus only,
not shown). PGH peptides showed a discrete localisation, in the
lateral portion of the median eminence, virtually completely
colocalised with GnRH (Fig. 2, I and J). The above distribution
profiles of VGF peptides in the POA and median eminence
remained broadly similar over the estrous cycle (not shown). In the
anterior pituitary (Fig. 2, K–Q), all VGF antisera labelled large
numbers of endocrine cells. The majority (80–90%) proved to be
LH containing gonadotrophes (Fig. 2, K–N and O, P: TLQP and
PGH peptides, respectively). A small proportion (about 10–20%)
of VGF C- or N-terminus, or PGH immunoreactive cells (Fig. 2,
O, Q) were prolactin containing lactotropes. In the morning
following estrus, immunostaining of gonadotropes (especially with
VGF C-and N-terminus and TLQP antibodies) was reduced, with
an increase of visible labeling in a fraction of lactotropes, as shown
previously [21] (Fig. 2, K, L versus M, N: diestrus versus estrus,
respectively).
In the ovary (Fig. 3), TLQP peptide immunoreactivity was
revealed in the granulosa (Fig. 3A) as well as in the theca and
interstitial cells (Fig. 3B). Conversely, PGH peptide/s were
restricted to oocytes (Fig. 3, C), and VGF C- and N- terminus
peptide labeling was scanty. In ovariectomised rats, most
hypertrophic pituitary gonadotropes showed VGF peptide immu-
noreactivity, with intense to moderate labeling intensity, as
reported previously [21].
Changes in cycling females
As with any other quantitative method based on the use of
antibodies, the numerical values of peptide concentrations
measured in ELISA ought to be considered with caution, pending
sequencing of the relevant native peptide/s, hence use of proper
standards.
Nonetheless, TLQP peptides appeared to be most abundant in
all areas we studied, as well as in plasma (Fig. 4), with lowest levels
for VGF C-and N-terminus peptides in ovary and plasma. Along
the estrous cycle, TLQP levels were higher during metestrus in
median eminence and during metestrus and diestrus in pituitary.
The same peptides were more abundant in ovary and lower in
plasma during proestrus, compared to the other phases. VGF C-
and N-terminus peptides, too, increased during metestrus and/or
diestrus in median eminence and pituitary, as well as in plasma.
PGH peptides failed to show significant modulation.
Ovariectomy and hormonal treatment
In the absence of hormonal treatment, upon ovariectomy
TLQP peptides were greatly reduced in plasma (roughly 20% of
average levels in cycling females: Figs. 4, 5). The other VGF
peptides studied were also decreased, to very low levels. As
measured in the ‘‘whole hypothalamus’’, post-ovariectomy TLQP
and PGH peptides were roughly comparable to cycling females,
while VGF N- and C-terminus peptides were reduced (Figs. 4, 5).
In the pituitary, most VGF peptides studied were distinctly
increased, except for VGF C-terminus containing ones. Upon
estrogen-progesterone treatment, a differential response was
shown for TLQP and VGF C-terminus peptides, both further
increasing in the pituitary, while in hypothalamus TLQP
increased, and VGF C-terminus peptides were reduced (Fig. 5).
In plasma, all VGF peptides studied showed a tendency to increase
after hormonal treatment, with significant differences for VGF N-
terminus peptides only.
Molecular heterogeneity
To resolve small to medium MW peptides we resorted to gel
chromatography, with detection by ELISA in view of its enhanced
selectivity for internally cleaved peptides (see above). Three major
peaks were shown for TLQP peptides (Fig. 6, left: a, b, c), closely
matching the elution positions shown previously for TLQP-62,
TLQP-30 and TLQP-21 [30]. Such forms were found in all tissues
studied and in plasma, with a lower TLQP-21 peak in the ovary.
Higher MW forms were seen, at approximately 10–12 kDa and in
the void volume, or in the region overlapping the void volume in
plasma (Fig. 6, left). VGF C-terminus immunoreactivity was
revealed in the void volume (Fig. 6, mid-left: d), compatible with
VGF precursor, and in a major broad peak in the approximately
10–15 kDa range (ibidem: e), possibly representing previously
described VGF18 or VGF20 [11,12]. A lower peak (ibidem: f)
appeared to relate to the TLQP ‘‘a’’ peak described above. The
same peptides were mostly seen as low MW fragments in the
ovary, while migrating as large forms in plasma (Fig. 6, mid-left).
The VGF N-terminus assay also showed abundant reactivity in the
large MW fractions from plasma (Fig. 6, mid-right: refer ‘‘g’’ to
bottom panel), with lower levels at varied MW in tissue extracts. In
the hypothalamus, the N-terminal VGF24–63 peptide [31] may
take part in the lower MW portion (Fig. 6, mid-right: h) of a
broad, approximately 3–10 kDa interval of immunoreactive
fractions. PGH peptides were revealed as different MW forms,
especially in the hypothalamus (Fig. 6, right). The largest MW
forms eluting in the void volume were low in tissues and abundant
in plasma (ibidem: i). Interestingly, an intermediate MW peak
(ibidem: m, roughly 30–50 kDa) might correspond to PGH
peptide/s encompassing the whole portion between the PGH
sequence and either of the known cleaved rat peptides: VGF180–
209, or VGF24–36 [31;32], see (Fig. 1). The low MW peak shown
(ibidem: n) fits well with the reported PGH8 peptide [33], running
between the PGH sequence and the immediately preceding
cleavage site (rat VGF: Lys421-Arg422).
In vitro experiments
A single dose of TLQP-21 was tested, comparable to the one
shown to induce release of GnRH from male rat hypothalami
[24]. Upon addition of TLQP-21 to the culture medium,
somatostatin release into the medium showed a non-significant
tendency to decrease (Fig. 7, left panel). Conversely, GHRH
release was significantly enhanced (approximately 50%, Fig. 7,
right panel).
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Figure 2. VGF peptide localisation in hypothalamus and pituitary. In the preoptic area (A–D), PGH peptides (A) were immunostained within
almost all neuronal terminals containing GnRH (B) conversely, VGF N-terminus peptides (C) were also revealed in most kisspeptin neuronal terminals
(D): A, C: Cy3 red labeling; B, D: Cy2 green labeling. In the median eminence (E–J), TLQP peptides (E) were selectively found in almost all somatostatin
neuronal terminals and axons (F). Conversely, VGF C-terminus (G) and PGH (I) antibodies labeled GnRH neurone terminals (H and J, respectively): E, G,
I: Cy3 red labeling; F, H, J: Cy2 green labeling. In the pituitary (K–Q), the number of cells positive with both TLQP (K, M) and LH (L, N) antibodies was
higher in diestrous (K, L) than in estrous phase (M, N). Conversely, the PGH peptides (O) were found in a large number of LH cells (P) and in a few PRL
cells (Q, colocalised cells are identified by the arrows). Scale bars: A–B, E–Q: 100 um, C–D: 50 um.
doi:10.1371/journal.pone.0108456.g002
Figure 3. VGF peptide localisation in Ovary. TLQP peptide immunoreactivity was found in the granulosa (A) as well as in the theca and
interstitial cells (B), while PGH peptides were restricted to the oocyte (C). All VGF staining: Cy3 red labeling. Scale bar: 50 um.
doi:10.1371/journal.pone.0108456.g003
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Discussion
Our study demonstrated the presence of several peptides
derived from the VGF precursor, with selective differential profiles
at all levels of the hypothalamic-pituitary-ovarian axis. A striking
modulation in peptide tissue levels including plasma was shown
across the estrous cycle, implicating VGF peptides in events and
mechanisms relevant to reproduction.
In view of the proposed role of VGF as multifunctional
precursor of bioactive peptides our study was focused on end
products of the VGF precursor, rather than on the primary VGF
gene product itself. The primary sequence of VGF shows at least
ten putative cleavage sites, in the form of two or more basic amino
acid residues, highly conserved across species. Recently, further
fragments including bioactive VGF peptides have been shown to
derive from cleavage at single basic amino acids [16,34,35]. In
view of the lower proteomic complexity of the cerebro-spinal fluid
(CSF), the precise chemical nature of VGF derived end products
has so far been mostly studied in such body fluid [36] with the
addition of neuro-endocrine cells lines [33]. An array of VGF
peptides and fragments have been revealed, with striking changes
in neurodegenerative and other disease conditions [37–40].
Certain VGF peptides proved to be released in vivo in the brain
upon neuronal depolarization [31] while an interactomic investi-
gation revealed selective domains of VGF, including the TLQP-21
region, as likely binding partners for the amyloid precursor protein
[41]. Similarly, two peptides derived from non-overlapping regions
of the VGF precursor were reported in the protein-bound and un-
bound fractions, respectively, from CSF [42]. In the present study,
TLQP-antibodies showed several chromatography peaks fitting
well with known VGF peptides, such as TLQP-21, -30 and -62
[30]. Products derived from the C-terminal domain of VGF have
been studied in some detail [11,12] and the major molecular
form/s we found in hypothalamus and pituitary may represent so-
called VGF18 and 20 (such denomination refers to migration in
western blot, not to MW). In connection with the TLQP-62 peak
shown here with the relevant N-terminal antibody (‘‘TLQP rat
556–565’’ antibody), a lower amount of reactivity was revealed in
chromatography with the corresponding C-terminus antibody.
The very high selectivity of such antibody that we found for the
unmodified C-terminal sequence suggests that TLQP-62 peptide/s
may partly undergo limited processing at their C-terminal end.
Other peptides derived from the C-terminal domain of the VGF
precursor may have gone undetected in our study, due to a degree
of processing or change at their C-terminus. At the other extreme
Figure 4. VGF peptide levels in cycling females. Levels of TLQP, C-/N- terminus and PGH peptides were measured in hypothalamus, median
eminence (M.E), pituitary, ovary and plasma in each phase of the estrous cycle. During metestrus and/or diestrus, enhancement was revealed for
TLQP and the C-/N-terminal peptides in M.E, pituitary and also in plasma. In the pro-estrous phase, exclusively TLQP peptides were found to be
increased in ovary and decreased in plasma. PGH peptides did not show any change. Pmol/g: picomoles per grams; pmol/ml: picomoles per millilitres;
*p,0.05, **p,0.005.
doi:10.1371/journal.pone.0108456.g004
VGF Peptides and Hypothalamus-Pituitary-Ovary Axis
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e108456
of VGF, a fully N-terminal 40 amino acid peptide has been proved
to be released upon neuronal depolarization [31]. Such peptide
may take part in a broad region of immunoreactivity we found in
the hypothalamus and probably elsewhere. A small PGH peptide
(‘‘PGH8’’), corresponding to a sequence running from the C-
terminal peptide sequence we used to raise antibodies (‘‘PGH
rat422–430’’ antibody), to the immediately preceding putative
cleavage site (Lys-Arg, rat VGF421–422, ‘‘R’’ preceding the
‘‘PGH rat 422–430’’) was demonstrated in mouse neuroblastoma
cells [33]. While several intermediate MW PGH peptides are
difficult to interpret, one may speculate that the broad immuno-
reactive peak close to the void volume that we found in gel
Figure 5. VGF peptide levels in ovariectomised (OVX) rats. Levels of TLQP, C-/N-terminus and PGH peptides were measured in the
hypothalamus (including median eminence), pituitary, and plasma of OVX rats with and without oestradiol-progesterone (EP) treatment: OVX+EP and
OVX, respectively. OVX+EP rats revealed an increase for TLQP peptides in hypothalamus and pituitary as well as changes for C-terminal peptides. In
plasma, after EP treatment an increase was revealed for N-terminal peptides only. The PGH peptides did not reveal any change. Pmol/g: picomoles
per grams; pmol/ml: picomoles per millilitres; *p,0.05, **p,0.005.
doi:10.1371/journal.pone.0108456.g005
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chromatography could include putative, large VGF fragments
running from the PGH sequence to a region close to the N-
terminus of VGF. In plasma, we revealed certain VGF peptides
possibly including TLQP-21, TLQP-30 and TLQP-62, however,
in general, a large MW peak was prominent with all VGF assays.
This may indicate that one or more VGF peptides travel in the
circulation bound to plasma proteins. In fact, many polypeptides
are known to bind to major plasma proteins, and/or to their
selective transporter/s. Concerning to our study, one ought to
notice that tissue extracts underwent at least some treatment steps
(e.g. heat tratment) which would reduce molecular interactions of
VGF peptides with other molecules, while plasma samples was
Figure 6. Sephadex chromatography. Three major peaks were shown for TLQP peptides (left: a, b, c), corresponding to TLQP-62, TLQP-30 and
TLQP-21 and found in all tissue extracts. Higher MW forms were seen, at approximately 10–12 kDa and in the void volume, or in the region
overlapping the void volume in plasma. VGF C-terminus immunoreactivity was revealed in the void volume (mid-left: d), compatible with VGF
precursor, and in a major broad peak in the approximately 10–15 kDa range (ibidem: e), while a lower peak (ibidem: f) appeared related to the TLQP
‘‘a’’ peak described above. The same peptides were mostly seen as low MW fragments in the ovary, while migrating as large forms in plasma (mid-
left). The VGF N-terminus assay revealed abundant reactivity in the large MW fractions from plasma (mid-right: refer ‘‘g’’ to bottom panel), with lower
levels at varied MW in the other tissue extracts. PGH peptides were revealed as different MW forms, especially in the hypothalamus while the largest
MW forms eluting in the void volume were abundant in plasma (ibidem: i). Molecular weight markers are shown with the corresponding arrows.
Pmol/f:picomoles/fraction; f:fraction.
doi:10.1371/journal.pone.0108456.g006
Figure 7. TLQP-21 in in vitro experiments. TLQP-21 included in the medium of hypothalamic samples up-regulates the secretion of growth-
hormone-releasing hormone (GHRH). Contr.: control medium analysed by ELISA without the addition of TLQP-21 versus the medium including the
peptide (TLQP column).
doi:10.1371/journal.pone.0108456.g007
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neither extracted, nor treated before assays. While examples of the
binding of VGF peptides to other components are provided above,
the possibility that at least some of the VGF-immunoreactive large
MW forms found in plasma may represent actual VGF precursor
cannot be excluded.
On this context, the selective differential MW profiles of the
VGF peptides were found in parallel with a striking modulation in
their tissue levels across the estrous cycle.
With respect to the TLQP peptides, as mentioned, they were
found within median eminence somatostatin neurones, gonado-
tropic and ovary cells with high tissue levels especially in ovary and
plasma. In the blood, their low levels in ovariectomised rats
showed the ovary as a major source of circulating TLQP peptides.
During the cycle, we showed an increase in pituitary TLQP levels
on metestrus–diestrus. This is according to the increase in LH
secretion obtained after TLQP-21 icv administration in adult
female rats on the same diestrous phase [25]. Moreover, we
reported here that, on proestrus, the TLQP ovary levels were
augmented, but during the following phases (including the
diestrus), the same ovary reduced its TLQP peptide content that
concurrently augmented in blood. The possible involvement of
TLQP peptides in endocrine mechanisms related to reproduction
is suggested also by the reported increase in LH secretion after
system ip administration of TLQP-21 on prepubertal rats [25].
Hence, from our results, one may hypothesize that during the
diestrus-metestrus, circulating TLQP peptides secreted from the
ovary, may stimulate the pituitary secretion of LH, perhaps
through an augment of the same TLQP content in the pituitary.
The involvement of TLQP peptides on female reproductive
mechanisms has so far been reported to be related to the LH
production at the pituitary [25] but not at the gonad level. As to
the potential TLQP receptors, the same C3a/C3AR1 molecules
that have been found to modulate the pituitary hormonal activity
[43] have been reported to be the targets of the TLQP-21 in the
hamster ovary cell lines [44]. Hence, the same ovary that secretes
TLQP peptides into the blood could be regulated by its own
derived peptides, or alternatively the circulating TLQP peptides
reacting to the ovary receptors could originate, at least in part,
from the hypophysis. This is suggested by our finding in estrous
phase, where a marked reduction in TLQP pituitary levels
(according to a minor number of immnolabeled cells) was found in
parallel with a TLQP plasmatic increase.
Moreover, we cannot exclude the possibility that TLQP
peptides could also act through a paracrine and/or autocrine
way, in view of their presence in the same organs (pituitary and
ovary) that contain their potential receptors. This autocrine/
paracrine role could involve the regulation of LH secretion,
according to the mentioned augment in TLQP pituitary levels on
the same phase in which the LH secretion was found to increase
[25]. Indeed, an autocrine role have been already demonstrated
for other VGF peptides as NERPs that being present within the
vasopressin cells, regulated the same vasopressin production
[16,34]. On the other end, our results showed also that TLQP
peptides in the pituitary and hypothalamus could be up-regulated
by the oestradiol/progesterone.
These hormones regulate also somatostatin [45], and being
TLQP peptides present in such neurones, it is possible that steroid
hormones could modulate both TLQP and somatostatin by the
same mechanisms. Regarding the role of TLQP peptides in the
median eminence, in view of their close relation to somatostatin
seen also in pancreas [46] and stomach [30], we tried to elucidate
a possible bioactivity of TLQP-21 on somatostatin and on its
GHRH neurone targets. We found that TLQP-21 up-regulated
the GHRH production suggesting that such peptide could act
promoting the growth at the hypothalamic level. When adult male
mice were chronically treated (by icv injection) with TLQP-21,
physiological, molecular and behavioral parameters related to the
GH axis were investigated, however, TLQP-21 did not modulate
the GH axis [47]. One could hypothesize that TLQP-21 may
regulate GHRH through somatostatin neurones selectively at the
median eminence level, instead when the same peptide is injected,
only a little part could reach the median eminence. Further
experiments are needed to ascertain the precise role of TLQP-21
on the growth mechanisms and the possible connections with the
cycle. Regarding the other VGF peptides, also C-and N-terminus
peptides changed in the hypothalamus, pituitary and plasma.
However, for these peptides is more difficult to hypothesize
mechanisms of action in view of the rare information regarding
their involvement on reproduction. It could be only suggested that
these peptides could have a neuroendocrine and/or endocrine
activity on the estrous cycle, and their presence into kisspeptin
neurones is intriguing because of the importance of this hormone
in reproductive mechanisms [48,49]. Furthermore, also the
presence of PGH peptides in gonadotrophs, GnRH neurones,
plasma and especially within the oocyte, needs more investigation.
In conclusion, various VGF peptides may regulate the hypothal-
amus-pituitary complex via specific neuroendocrine mechanisms.
In particular, for TLQP peptides we may hypothesize different
possible interacting ways of action on the reproduction including
endocrine pathways largely involving the ovary as well as
paracrine/autocrine mechanisms at both the pituitary and ovary
levels.
In addition, we also found evidence for an involvement of
TLQP-21 on neuroendocrine mechanisms acting on promoting
growth at the median eminence level.
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